article thumbnail

Regional inequalities threatening Europe’s biosimilars market

European Pharmaceutical Review

With procurement practices across Europe having a strong price focus, over time, this could impact the “sustainability of biosimilars and decrease competition, as well as reducing supply reliability”, the report acknowledged. “As Act4Biosimilars is supported by its founding sponsor, Sandoz.

Marketing 110
article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

He focuses his practice on EU regulatory affairs, litigation and competition law issues affecting the life sciences sector in Europe. In addition to advising on EU life sciences matters, Maarten also handles competition litigation at the EU and national levels. Maarten has significant competition law experience in a variety of sectors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Katie Porter attacks pharma

World of DTC Marketing

2wo: The number of mergers and acquisitions(M&A) involving one of the top 25 firms in the pharmaceutical industry more than doubled from 2006 to 2016, and the practice doesn’t seem to be abating. So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%).

Pharma 187
article thumbnail

Merck defends blockbuster Januvia franchise from patent challenge

pharmaphorum

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. billion in the first half of 2022.

article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Currently, 40 biosimilars are FDA-approved and 25 have launched, whereas the EMA has approved 86 biosimilars since 2006. The biosimilar market in the US may progress differently this time.

article thumbnail

The Evolution of Biosimilars from Their Beginning Until Now—And What’s Next

PM360

Chrys Kokino has been involved in the biosimilars market prior to the first biosimilar being approved in Europe in 2006. From that point in 2006 all the way to where we are currently today, there has been a very dramatic evolution of these products. The level of competition is much greater today then we previously anticipated.

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

Pharma 64